Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human KLC1 ELISA Kit (AC3082)
Cat.#: ASET-1671
Specifications
Description Human KLC1 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human KLC1 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 2.44 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 75-1200 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1783 Mouse DDR2 ELISA Kit (AC3194) Quantitative inquiry ASET-1186 Human TRPC5 ELISA Kit (AC2597) Quantitative inquiry ASET-2478 Human RAMP1 ELISA Kit (AC3889) Quantitative inquiry ASET-2200 Mouse PGRPS ELISA Kit (AC3611) Quantitative inquiry ASET-2126 Human LAMC2 ELISA Kit (AC3537) Quantitative inquiry ASET-1387 Human beta 1 Adrenergic Receptor ELISA Kit (AC2798) Quantitative inquiry ASET-1105 Human KCNK6 ELISA Kit (AC2516) Quantitative inquiry ASET-2076 Human EDG8 ELISA Kit (AC3487) Quantitative inquiry ASET-2072 Mouse GDF11 ELISA Kit (AC3483) Quantitative inquiry ASET-1631 Rabbit eNOS ELISA Kit (AC3042) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket